Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,651 GBX | +0.70% | +2.51% | +13.85% |
Apr. 23 | Edwards Lifesciences Corporation: The story continues | |
Apr. 22 | European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+13.85% | 83.92B | B | ||
+27.92% | 672B | C+ | ||
+27.68% | 570B | B | ||
-4.59% | 360B | C+ | ||
+16.38% | 321B | B- | ||
+9.39% | 300B | C+ | ||
+6.30% | 217B | B+ | ||
+4.80% | 199B | B- | ||
-6.05% | 204B | A+ | ||
-8.58% | 149B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GSK Stock
- Ratings GSK plc